Your browser is no longer supported. Please, upgrade your browser.
Cytosorbents Corporation
Index- P/E- EPS (ttm)-0.21 Insider Own4.40% Shs Outstand43.24M Perf Week-1.31%
Market Cap351.84M Forward P/E156.60 EPS next Y0.05 Insider Trans0.00% Shs Float39.55M Perf Month-11.89%
Income-8.60M PEG- EPS next Q-0.04 Inst Own43.20% Short Float5.64% Perf Quarter-27.07%
Sales42.90M P/S8.20 EPS this Y66.20% Inst Trans0.96% Short Ratio8.07 Perf Half Y0.48%
Book/sh1.79 P/B4.64 EPS next Y133.30% ROA-10.30% Target Price- Perf Year-19.81%
Cash/sh1.62 P/C5.14 EPS next 5Y- ROE-13.10% 52W Range7.13 - 11.74 Perf YTD4.14%
Dividend- P/FCF- EPS past 5Y11.90% ROI-11.70% 52W High-29.30% Beta0.28
Dividend %- Quick Ratio7.80 Sales past 5Y53.60% Gross Margin73.40% 52W Low16.41% ATR0.35
Employees195 Current Ratio8.20 Sales Q/Q21.80% Oper. Margin-25.00% RSI (14)42.42 Volatility4.78% 4.15%
OptionableYes Debt/Eq0.00 EPS Q/Q5.10% Profit Margin-19.90% Rel Volume0.42 Prev Close8.13
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume276.36K Price8.30
Recom1.70 SMA20-5.00% SMA50-5.46% SMA200-5.98% Volume115,227 Change2.09%
Sep-17-20Initiated Jefferies Buy $15
Sep-01-20Initiated SVB Leerink Outperform $15
Aug-08-17Reiterated Maxim Group Buy $10 → $12
Oct-26-16Initiated Aegis Capital Buy
May-24-16Initiated Maxim Group Buy $8
Oct-29-15Upgrade WBB Securities Speculative Buy → Buy $13 → $13
May-12-15Reiterated MLV & Co Buy $28 → $21
Apr-01-15Reiterated MLV & Co Buy $28 → $30
Mar-05-15Initiated MLV & Co Buy $30
Feb-25-15Initiated WBB Securities Speculative Buy $13
Jan-27-15Reiterated H.C. Wainwright Buy $1 → $12
May-11-21 03:30PM  
May-04-21 04:15PM  
Apr-27-21 01:55PM  
Apr-19-21 12:22PM  
Apr-17-21 03:49AM  
Mar-29-21 07:08AM  
Mar-16-21 03:15PM  
Mar-12-21 07:00AM  
Mar-09-21 04:28PM  
Mar-08-21 10:10AM  
Mar-02-21 07:00AM  
Mar-01-21 06:00PM  
Feb-24-21 07:08AM  
Feb-18-21 07:08AM  
Feb-16-21 07:08AM  
Feb-04-21 07:08AM  
Jan-26-21 01:02AM  
Jan-21-21 07:08AM  
Jan-19-21 07:08AM  
Jan-12-21 07:00AM  
Jan-11-21 06:00AM  
Jan-04-21 06:30AM  
Dec-17-20 07:08AM  
Dec-13-20 09:44PM  
Dec-10-20 07:00AM  
Dec-09-20 06:45AM  
Dec-02-20 07:08AM  
Nov-25-20 07:08AM  
Nov-23-20 07:00AM  
Nov-12-20 02:00AM  
Nov-10-20 05:25AM  
Nov-06-20 06:05AM  
Nov-04-20 08:31PM  
Nov-03-20 10:08AM  
Oct-21-20 07:08AM  
Oct-14-20 07:00AM  
Oct-09-20 07:08AM  
Sep-21-20 07:08AM  
Sep-19-20 10:45AM  
Sep-11-20 08:00AM  
Sep-08-20 07:08AM  
Sep-01-20 04:50PM  
Aug-24-20 07:00AM  
Aug-17-20 07:08AM  
Aug-06-20 09:05AM  
Aug-05-20 09:01AM  
Aug-04-20 05:18PM  
Aug-03-20 12:47PM  
Jul-31-20 07:08AM  
Jul-28-20 07:08AM  
Jul-22-20 12:31PM  
Jul-21-20 03:48PM  
Jul-20-20 04:51PM  
Jul-08-20 07:00AM  
Jun-29-20 07:08AM  
Jun-25-20 12:27PM  
Jun-24-20 07:30AM  
Jun-19-20 05:40AM  
Jun-09-20 07:08AM  
Jun-06-20 08:05AM  
May-27-20 12:00PM  
May-19-20 08:03AM  
May-12-20 07:08AM  
May-08-20 02:24PM  
May-06-20 03:01PM  
May-05-20 04:15PM  
May-04-20 07:08AM  
Apr-28-20 08:00AM  
Apr-27-20 07:08AM  
Apr-20-20 06:58AM  
Apr-15-20 07:00AM  
Apr-13-20 03:31PM  
Apr-03-20 12:06PM  
Mar-31-20 07:08AM  
Mar-30-20 04:23PM  
Mar-25-20 07:19AM  
Mar-12-20 09:33AM  
Mar-05-20 04:15PM  
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BLOCH KATHLEEN P.Chief Financial OfficerDec 31Option Exercise5.607,85743,999333,013Jan 04 04:30 PM
Kraus AlDirectorNov 10Option Exercise3.458,00027,600133,046Nov 12 05:31 PM
Kraus AlDirectorNov 10Sale8.008,00064,000125,046Nov 12 05:31 PM
Jones Edward RaymondDirectorAug 18Option Exercise3.354,00013,40078,800Aug 20 04:10 PM
BLOCH KATHLEEN P.Chief Financial OfficerJul 31Option Exercise5.6010,00056,000325,156Aug 04 04:31 PM